Goodwin Advises PepGen on $125 Million Public Offering of Common Stock
The Life Sciences team advised PepGen Inc. (PepGen) on the public offering of 25,000,000 shares of its common stock at a price to the public of $5.00 per share. The aggregate gross proceeds to PepGen from this offering were $125 million, before deducting underwriting discounts and commissions and offering expenses. In addition, PepGen has granted the underwriters a 30-day option to purchase up to an additional 3,750,000 shares of common stock at the public offering price, less the underwriting discounts and commissions. The offering closed on November 13, 2026.
PepGen Inc. is a clinical-stage biotechnology company pioneering oligonucleotide therapies with the potential to transform the treatment of rare genetic diseases. Founded on more than a decade of research and development, PepGen’s Enhanced Delivery Oligonucleotide (EDO) technology leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Using this EDO technology, PepGen is advancing PGN-EDODM1, a clinical candidate for the treatment of myotonic dystrophy type 1.
The Goodwin team was led by Edwin O'Connor, Jon Burr, Kristen Rafael, Swetha Gopalakrishnan, Brandon Richards, Amelia Nell, and Julie Tibbets.
For more information on the deal, please read the press release.